Evolving Paradigms in Melanoma Therapy

November 6, 2015

Learning Objectives

  • Describe the mechanism of action for talimogne laherparepvec (T-VEC)
  • Describe how checkpoint inhibitors, both CTLA-4 and PD-L1, alter the body’s immune response to melanoma cells
  • Describe potential toxicities associated with checkpoint inhibitors, including etiology of these toxicities and management and/or prophylaxis
  • Explain how checkpoint inhibitors differ from other available treatment options for metastatic melanoma, including kinase inhibitors and cytotoxic chemotherapy
  • Discuss the role of the advanced practitioner as part of the collaborative practice team in caring for patients on immunotherapy treatments
Course summary
Available credit: 
  • 1.00 AANP
  • 0.83 Pharmacology
  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
  • 1.00 ANCC
Course opens: 
11/06/2015
Course expires: 
02/29/2016
Event starts: 
11/06/2015 - 4:40pm
Event ends: 
11/06/2015 - 5:40pm
Cost:
$0.00
Parent activity set: 
Concurrent Sessions 4:40-5:40PM
Add to calendar: 
Rating: 
0
United States

Anthony J. Olsznaski, MD, RPH
Brianna Hoffner, MS, ANP-BC, AOCNP

Available Credit

  • 1.00 AANP
  • 0.83 Pharmacology
  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
  • 1.00 ANCC

Price

Cost:
$0.00
Please login or register to take this course.